Connection

Don Rockey to Hypertension, Portal

Back to Details
This is a "connection" page, showing publications Don Rockey has written about Hypertension, Portal.
Don Rockey
Connection Strength
9.112
Hypertension, Portal
  1. The relationship between portal hypertension and portal hypertensive gastropathy. Scand J Gastroenterol. 2022 Mar; 57(3):340-344.
    View in: PubMed
    Score: 0.756
  2. Lower Gastrointestinal Bleeding in Patients With Cirrhosis-Etiology and Outcomes. Am J Med Sci. 2020 04; 359(4):206-211.
    View in: PubMed
    Score: 0.662
  3. An Update: Portal Hypertensive Gastropathy and Colopathy. Clin Liver Dis. 2019 11; 23(4):643-658.
    View in: PubMed
    Score: 0.645
  4. The Molecular Basis of Portal Hypertension. Trans Am Clin Climatol Assoc. 2017; 128:330-345.
    View in: PubMed
    Score: 0.536
  5. A New Treatment for Portal Hypertension? Gastroenterology. 2016 05; 150(5):1077-1080.
    View in: PubMed
    Score: 0.508
  6. The Beneficial Effect of Beta-Blockers in Patients With Cirrhosis, Portal Hypertension and Ascites. Am J Med Sci. 2016 Feb; 351(2):169-76.
    View in: PubMed
    Score: 0.503
  7. Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions. J Hepatol. 2014 Oct; 61(4):912-24.
    View in: PubMed
    Score: 0.449
  8. Portal hypertensive gastropathy and colopathy. Clin Liver Dis. 2014 May; 18(2):389-406.
    View in: PubMed
    Score: 0.446
  9. Hepatic hydrothorax: clinical features, management, and outcomes in 77 patients and review of the literature. Medicine (Baltimore). 2014 May; 93(3):135-142.
    View in: PubMed
    Score: 0.446
  10. Long-term follow-up of TIPS created with expanded poly-tetrafluoroethylene covered stents. Dig Dis Sci. 2013 Jul; 58(7):2100-6.
    View in: PubMed
    Score: 0.409
  11. Portal hypertensive gastropathy: a review. Liver Int. 2010 Sep; 30(8):1094-102.
    View in: PubMed
    Score: 0.340
  12. Endothelin antagonism in portal hypertensive mice: implications for endothelin receptor-specific signaling in liver disease. Am J Physiol Gastrointest Liver Physiol. 2009 Jul; 297(1):G27-33.
    View in: PubMed
    Score: 0.313
  13. Noninvasive assessment of liver fibrosis and portal hypertension with transient elastography. Gastroenterology. 2008 Jan; 134(1):8-14.
    View in: PubMed
    Score: 0.287
  14. Hepatic fibrosis, stellate cells, and portal hypertension. Clin Liver Dis. 2006 Aug; 10(3):459-79, vii-viii.
    View in: PubMed
    Score: 0.261
  15. Pharmacologic therapy for gastrointestinal bleeding due to portal hypertension and esophageal varices. Curr Gastroenterol Rep. 2006 Feb; 8(1):7-13.
    View in: PubMed
    Score: 0.252
  16. A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension. Nat Med. 2005 Sep; 11(9):952-8.
    View in: PubMed
    Score: 0.245
  17. Review article: controversies surrounding the use of carvedilol and other beta blockers in the management of portal hypertension and cirrhosis. Aliment Pharmacol Ther. 2023 Mar; 57(5):454-463.
    View in: PubMed
    Score: 0.204
  18. A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis. Hepatology. 2021 12; 74(6):3146-3160.
    View in: PubMed
    Score: 0.189
  19. Cellular pathophysiology of portal hypertension and prospects for management with gene therapy. Clin Liver Dis. 2001 Aug; 5(3):851-65.
    View in: PubMed
    Score: 0.184
  20. Vasoactive agents in intrahepatic portal hypertension and fibrogenesis: implications for therapy. Gastroenterology. 2000 Jun; 118(6):1261-5.
    View in: PubMed
    Score: 0.170
  21. ?-Arrestin2 is a critical component of the GPCR-eNOS signalosome. Proc Natl Acad Sci U S A. 2020 05 26; 117(21):11483-11492.
    View in: PubMed
    Score: 0.169
  22. Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension. J Clin Invest. 2000 Mar; 105(6):741-8.
    View in: PubMed
    Score: 0.167
  23. Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension. Hepatology. 2019 03; 69(3):1287-1299.
    View in: PubMed
    Score: 0.155
  24. Transjugular intrahepatic portosystemic shunt (TIPS) in patients with refractory ascites: effect on body weight and Child-Pugh score. Am J Gastroenterol. 1998 Oct; 93(10):1891-4.
    View in: PubMed
    Score: 0.151
  25. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology. 1998 Feb; 114(2):344-51.
    View in: PubMed
    Score: 0.145
  26. New concepts in the pathogenesis of portal hypertension: hepatic wounding and stellate cell contractility. Clin Liver Dis. 1997 May; 1(1):13-29.
    View in: PubMed
    Score: 0.137
  27. The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide. Hepatology. 1997 Jan; 25(1):2-5.
    View in: PubMed
    Score: 0.134
  28. G-protein-coupled receptor kinase interactor-1 (GIT1) is a new endothelial nitric-oxide synthase (eNOS) interactor with functional effects on vascular homeostasis. J Biol Chem. 2012 Apr 06; 287(15):12309-20.
    View in: PubMed
    Score: 0.095
  29. Using capsule endoscopy to identify GI tract lesions in cirrhotic patients with portal hypertension and chronic anemia. J Clin Gastroenterol. 2008 Aug; 42(7):844-8.
    View in: PubMed
    Score: 0.075
  30. Hepatic tissue endothelin-1 levels in chronic liver disease correlate with disease severity and ascites. Am J Gastroenterol. 2000 Jan; 95(1):199-203.
    View in: PubMed
    Score: 0.041
  31. Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. Gastroenterology. 2018 10; 155(4):1140-1153.
    View in: PubMed
    Score: 0.037
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.